This is why it is so important to deal with the risk factors of a potentially severe course of COVID-19, and new glucose-lowering drugs such as GLP-1 RAs reducing impairment of multi-organ metabolic disorders are the key to improve prognosis and survival of DM 2 patients [118,119]. The gene discussed is GCG; the disease is COVID-19.